Release Tx to present CNS protein delivery data at summit in Boston

Release Therapeutics will present new preclinical data on its Myo-P4 platform at the 8th Annual CNS Drug Delivery Summit in Boston from Dec. 1-3, 2026. The poster is designed to spotlight the company’s broader effort to deliver therapeutic proteins to the central nervous system for rare pediatric neurological diseases.

Why it matters: - Release Therapeutics is trying to make sustained protein delivery to the central nervous system more practical for hard-to-treat neurological diseases. - The company’s lead program, Myo-P4, targets metachromatic leukodystrophy, a rare disorder that affects young children. - If successful, the platform could support long-term delivery of enzymes, antibodies and cytokines without repeated dosing.

What happened: - Release Therapeutics said it will showcase the Myo-P® platform at the 8th Annual CNS Drug Delivery Summit in Boston, Massachusetts, from Dec. 1 to 3, 2026. - The company’s abstract was selected for the Summit’s Scientific Poster Session. - Delphine Knittel, PhD, head of operations at Release Therapeutics, will present the poster on Wednesday, Dec. 2, 2026, at 14:40 EST. - The poster title is “Myo-P4, a CNS delivery system to treat Metachromatic Leukodystrophy (MLD).”

The details: - Myo-P® is a modular encapsulated cell technology platform built to provide sustained secretion of disease-specific therapeutic proteins. - The platform combines genetically engineered, immortalized human myoblasts with the Myo-Pod®, a patented biocompatible hollow-fibre device. - Release Therapeutics says the Myo-Pod is no larger than a pin. - The device has been evaluated after subdural implantation in large-animal models and after subcutaneous implantation in clinical studies. - The myoblast cell line has been engineered to produce antibodies, enzymes and cytokines. - Sustained protein secretion has been demonstrated in vivo for more than 10 months. - The Myo-Pod device is cargo-agnostic. - The broader encapsulated cell technology has been evaluated after subdural, subcutaneous and peritumoural implantation. - Release Therapeutics is also developing Myo-P5A for Sanfilippo syndrome type IIIA, or MPS IIIA, with the University of Geneva. - Myo-P4 is being developed in collaboration with the Paris Brain Institute. - The company says the platform has a long IP runway and external validation from Cell Press publications, competitive Innosuisse funding and the 2026 Disruptive Innovation Award from Geneva University Hospitals. - Research using Release Tx’s licensed ECT also helped earn the 2026 Pfizer Research Prize in Oncology for researchers at Geneva University Hospitals and the University of Geneva.

Between the lines: - The poster presentation gives Release Therapeutics a venue to show that the platform is not just a single-program concept. - The company is framing Myo-P® as a broader delivery system that could move across multiple CNS and non-CNS applications. - The mix of academic partnerships and awards suggests the company is trying to build credibility around both the science and the translational path.

What's next: - Release Therapeutics will present the poster during the summit’s scientific program on Dec. 2. - The company will likely use the meeting to push interest in Myo-P4 and the broader Myo-P® platform among researchers, investors and industry partners. - The summit, organized by Hanson Wade, will focus on technologies that improve CNS exposure and help overcome the blood-brain barrier.

The bottom line: - Release Therapeutics is betting that sustained CNS protein delivery can open a new path for rare pediatric neurological diseases, and the Boston summit is its latest test case. - For more information, visit the summit website or Release Therapeutics.